Skip to search formSkip to main contentSkip to account menu

LB-100

Known as: PP2A Inhibitor LB-100, Protein Phosphatase 2A Inhibitor LB-100 
A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Bridged Bicyclo Compounds, HeterocyclicPiperazines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract P5-03-02: Pre-clinical investigation of PP2A inhibitor LB-100 in overcoming and preventing lapatinib resistance in HER2-positive breast cancer
Background: HER2-positive breast cancer (BC) accounts for approximately 15% of all BC. HER2-targeted therapies, such as… 
2018
2018
Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer.
e13021Background: We have previously shown that protein phosphatase 2A (PP2A) may mediate acquired lapatinib resistance and… 
2018
2018
Abstract LB-100: Targeting TMEM205 mechanotransduction pathway using oncolytic virus therapy in ovarian clear cell carcinoma (OCCC)
  • U. Saini
  • Experimental and Molecular Therapeutics
  • 2018
  • Corpus ID: 81532686
Objectives: Ovarian clear cell carcinoma (OCCC) is an aggressive form of ovarian cancer and unfavorable treatment outcomes have… 
2017
2017
Evidence that PP2A activity is dispensable for spindle assembly checkpoint-dependent control of Cdk1
Progression through mitosis, the cell cycle phase deputed to segregate replicated chromosomes, is granted by a protein… 
2017
2017
Abstract LB-193: Protein phosphatase 2A inhibition,with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD1 blockade in a preclinical…
LB-100 is a novel, first-in-class, small molecule inhibitor of protein phosphatase 2A (PP2A) recently shown in a Phase I trial to… 
2016
2016
Disclosure of Potential Conflicts of Interests
  • 2016
  • Corpus ID: 27695813
s should appear on the third page of the manuscript. All information in the abstract should be consistentwith the information in… 
2015
2015
Su1990 A New Technology for the Classification of Patients With Gastric Adenocarcinoma Based on Differential Scanning Calorimetry Serum Thermograms
2015
2015
Su1991 Surveillance Strategy Based on the Incidence and Patterns of Recurrence After Curative Endoscopic Submucosal Dissection for Early Gastric Cancer
2015
2015
Abstract LB-100: Development of novel selective tumor-associated carbonic anhydrase inhibitors as promising anticancer agents
The molecular complexity of cancers and therapy-related side effects often limit efficacy of numerous anti-tumor therapies, and… 
2010
2010
Abstract LB-100: Optimal modulation of DNA repair in CLL therapy
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Resistance to chlorambucil (CLB) in chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)